Pharmaceutical Preparations · A1 · CIK 1540159
Edesa Biotech develops innovative drug candidates for inflammatory and immune-related diseases, focusing on dermatology and respiratory conditions
Comparable business profile · signals at a glance
In the 90 days to Mar 10, 2026: 2 insiders bought $233K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 1,000 | $6.60 | $7K |
| Mar 5, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 10,000 | $3.90 | $39K |
| Mar 4, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 10,000 | $4.26 | $43K |
| Mar 3, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 10,000 | $3.63 | $36K |
| Mar 2, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 2,000 | $2.00 | $4K |
| Mar 2, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 1,000 | $2.28 | $2K |
| Feb 27, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 30,000 | $2.22 | $67K |
| Feb 26, 2026 | Nijhawan PardeepChief Executive Officer | Buy | 20,571 | $1.58 | $33K |
| Feb 26, 2026 | Brooks Michael JPresident | Buy | 2,000 | $1.57 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.